T-cell acute lymphoblastic leukemia (T-
STAT5 represents one of the downstream effectors of IL7R/JAK signaling and activating STAT5B mutations have only recently been suggested to be leukemogenic in 2% of adults with large granular lymphocyte leukemia (6) and also in T-ALL (7, 8) . Here, we aimed at identifying novel leukemogenic driver mutations and first analyzed trios of bone marrow DNA of 5 patients with T-cell acute lymphoblastic leukemia obtained at initial diagnosis, remission and relapse. Exome sequencing revealed somatic nonsynonymous mutations in NOTCH1(3/10), PHF6 (2/10) genes which are involved in T-ALL leukemogenesis (9-11) and a missense mutation in STAT5B in two patients resulting in amino acid substitution N642H in the phosphotyrosine binding pocket of the SH2 domain of STAT5B. According to the allele frequency (AF), one patient was homozygous at relapse (AF=0.78, proportion of blasts 0.72).
The same mutation was detected in the primary disease sample with an AF of 0.43, indicating that either it was present in a heterozygous state in approximately all leukemic blasts or that it was in a homozygous state in approximately half of the leukemic blasts. These somatic genotypes were confirmed by Sanger sequencing. Sanger sequencing of xenograft cells confirmed a homozygous STAT5B N642H mutation in one of the patients at relapse; however, in the primary disease sample from this patient, the mutation was not detected in the xenograft cells although the other mutations detected by WES were confirmed by Sanger sequencing. In the second patient, STAT5B N642H was detected only at first diagnosis (AF 0.48), not at relapse (0 variant reads, coverage 176), indicating that treatment had reduced the leukemic clone carrying the STAT5B mutation by more than 99%. In the xenograft cells from the second patient, STAT5B N642H was detected in the sample from primary disease at a low AF (estimated 10%).
Sequencing of STAT5B exon 16 (which contains position 642) in the cohort of 301 children with primary T-ALL identified the N642H mutation in 19 samples (6.3%) . No other mutations in this exon were detected. For patients carrying the STAT5B mutation, there was a trend towards older age (>10 years) and male sex, but no correlation with treatment response as measured by prednisone response or PCR-based MRD kinetics (Table 1) . However, patients carrying the STAT5B N642H mutation were at significantly higher risk of relapse (pCIR 0.26) compared to STAT5B wild type patients (pCIR 0.11; relative risk 2.47, p= 0.038; Figure 1A ) with a trend towards poorer event free survival in STAT5B mutated patients (pEFS 0.74 vs. 0.81; Figure 1B ). The presence of the STAT5B N642H mutation was not significantly associated with the presence or absence of mutations in NOTCH1, PTEN, JAK1 or IL7R. By Sanger sequencing, we did not identify somatic PTPN2 mutations in our patient cohort. As reported before, NOTCH1 mutations were associated with a better early response to treatment and a reduced risk of relapse, while for PTEN mutations the opposite was observed (12) . The additional effect of STAT5B N642H on the risk of developing a relapse could not be subjected to a meaningful statistical analysis because of small sample sizes of the subgroups.
Consistent with the observation that T-ALL patients with STAT5B N642H carry an increased risk of relapse, of the 78 patients who had been treated according to the ALL-REZ BFM 95/96 and 2002 trials, 7 carried the STAT5B N642H mutation (9%). As in primary disease, there were no significant differences between STAT5B wild type and STAT5B N642H patients with regard to age, sex, immunophenotype, time to relapse and outcome. 5-year event free survival after first relapse was 14.3% in STAT5B N642H patients and 27.6% in STAT5B wild type patients (not significant, p=0.611). target genes that was independent from IL3 ( Figure 2E ).
Recently, the same mutation has been found in 1/15 pediatric and 5/84 adult T-ALL patients in addition to four other STAT5B mutations in adult T-ALL patients (S434L, T648S, Y665F, I704L) (7, 8) .
In large granular lymphocytic leukemia, the STAT5B N642H mutation has been shown to be involved in constitutive phosphorylation, nuclear localization and enhanced transcriptional activity of STAT5B in a reporter gene assay (6).
Because human STAT5A and STAT5B show 92% identity and can substitute each other in many, but not all functions (14) , one might hypothesize that STAT5A and STAT5B may be redundant proteins and subjected to the same mode of activation in T-ALL. However, an analysis of the corresponding area in STAT5A in our cohort of relapsed pediatric T-ALL did not reveal any mutations including position N642H. This finding is in line with the observation that activation of STAT5B, but not STAT5A, supports proliferation in squamous cell carcinoma (15) . Further, we did not find mutations in the SH2-domain of STAT3 indicating that STAT5B is unique within the STAT family in its ability to promote pediatric T-ALL.
The increased risk of developing a relapse in STAT5B N642H mutated patients as reported here represents an important clinical finding. As STAT5B N642H seems to be independent both from established risk factors such as MRD response and from other genetic markers such as activating NOTCH1 mutations, it may contribute to risk stratification algorithms of pediatric T-ALL in case this effect is confirmed in current T-ALL treatment protocols.
In conclusion, we demonstrate here that a common mutation of STAT5B Conflict-of-interest disclosure: The authors declare no competing financial interests. Tables   Table 1 Clinical and genetic characteristics of 301 T-ALL patients treated in the ALL-BFM 2000 study according to STAT5B mutational status. Expression of the STAT5 target genes BCL2, PIM1 and SOCS2 was quantified by RT-PCR. *p=0.05, **p=0.01, ***p=0.001, ****p=0.0001
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